A client prescribed carbamazepine is experiencing autoinduction of hepatic enzymes. What should the nurse anticipate?

A. The healthcare provider will monitor for liver failure: Carbamazepine induces hepatic enzymes, increasing its own metabolism rather than directly causing hepatic failure. Liver function tests may be monitored, but autoinduction primarily affects serum drug levels. The key concern is reduced therapeutic concentration rather than acute hepatotoxicity. B. The healthcare provider will increase the dose: Autoinduction leads to increased hepatic metabolism of carbamazepine over time, resulting in lower plasma drug levels despite adherence. To maintain therapeutic concentrations and seizure control, the dose is often gradually increased. This adjustment compensates for enhanced enzymatic clearance. C. The healthcare provider will discontinue the drug: Autoinduction is a predictable pharmacokinetic property of carbamazepine and does not require discontinuation when managed appropriately. The medication remains effective with dose adjustments. Discontinuation would risk seizure recurrence. D. The healthcare provider will decrease the dose: Decreasing the dose would further reduce already declining serum levels caused by enzyme induction. This could lead to subtherapeutic concentrations and breakthrough seizures.